179 related articles for article (PubMed ID: 8553904)
1. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
[TBL] [Abstract][Full Text] [Related]
2. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors.
Lissoni P; Rovelli F; Tisi E; Brivio F; Ardizzoia A; Barni S; Tancini G; Saudelli M; Cesana E; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(4):146-9. PubMed ID: 8844339
[TBL] [Abstract][Full Text] [Related]
3. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
Lissoni P; Tisi E; Brivio F; Ardizzoia A; Crispino S; Barni S; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1991; 5(4):154-6. PubMed ID: 1803863
[TBL] [Abstract][Full Text] [Related]
4. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
[TBL] [Abstract][Full Text] [Related]
5. A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors.
Lissoni P; Brivio F; Fumagalli L; Galimberti C; Cataldo M; Marsili MT; Brivio O; Barni S; Tancini G; Angelini A
J Biol Regul Homeost Agents; 1994; 8(1):32-5. PubMed ID: 7976492
[TBL] [Abstract][Full Text] [Related]
6. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
Lissoni P; Brivio F; Viviani S; Fumagalli L
J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
[TBL] [Abstract][Full Text] [Related]
7. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
Crispino S; Lissoni P; Ardizzoia A; Rovelli F; Perego MS; Grassi MG; Barni S; Pittalis S; Tancini G
J Biol Regul Homeost Agents; 1993; 7(3):92-4. PubMed ID: 8135145
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani GS
Anticancer Res; 2007; 27(4C):2985-8. PubMed ID: 17695482
[TBL] [Abstract][Full Text] [Related]
9. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
[TBL] [Abstract][Full Text] [Related]
10. [Mononuclear cell activation in Crohn's disease. Evaluation using serum assay of neopterin and interleukin-2 soluble receptors].
Duclos B; Reimund JM; Lang JM; Coumaros G; Chamouard P; Lehr L; Baumann R; Koehl C; Weill JP
Gastroenterol Clin Biol; 1990; 14(1):22-7. PubMed ID: 2311849
[TBL] [Abstract][Full Text] [Related]
11. Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2.
Di Felice G; Fumagalli L; Majorca F; Barni S; Ardizzoia A; Tancini G; Lissoni P
J Biol Regul Homeost Agents; 1996; 10(4):98-9. PubMed ID: 9604779
[TBL] [Abstract][Full Text] [Related]
12. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
[TBL] [Abstract][Full Text] [Related]
13. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
14. Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.
Skog AL; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
Cancer Immunol Immunother; 2002 Jul; 51(5):255-62. PubMed ID: 12070712
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
Zhang GJ; Adachi I
Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.
Clements PJ; Peter JB; Agopian MS; Telian NS; Furst DE
J Rheumatol; 1990 Jul; 17(7):908-10. PubMed ID: 2213757
[TBL] [Abstract][Full Text] [Related]
18. Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia.
Lissoni P; Brivio F; Fumagalli L; Messina G; Secreto G; Romelli B; Fumagalli G; Rovelli F; Colciago M; Brera G
In Vivo; 2007; 21(4):647-50. PubMed ID: 17708360
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of erythrosedimentation rate in cancer in relation to cytokine production: correlation with high IL-6 and low IL-2 blood concentrations.
Lissoni P; Brivio F; Pittalis S; Rovelli F; Rescaldani R; Perego MS; Grassi MG; Barni S; Tancini G; Majorca F; Fumagalli L
J Biol Regul Homeost Agents; 1996; 10(2-3):60-2. PubMed ID: 9250887
[TBL] [Abstract][Full Text] [Related]
20. Neopterin in renal cell carcinoma: inhalational administration of interleukin-2 is not accompanied by a rise of urinary neopterin.
Melichar B; Solichová D; Svobodová I; Melicharová K
Luminescence; 2005; 20(4-5):311-4. PubMed ID: 16134219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
